HeartSciences obtains FDA 510(k) clearance for MyoVista wavECG device
HeartSciences Inc. received FDA 510(k) clearance (K260005) for its MyoVista® wavECG device, a 12‑lead resting electrocardiograph for adult and pediatric patients. The clearance does not cover the company’s AI‑ECG algorithm and the firm said it will not commercialize the device until the AI component is cleared. The company also reaffirmed that its proposed merger with Fortitude Mining Holdings is still expected to close in the fourth quarter of 2026, subject to shareholder approval.
Why it matters
The clearance gives HeartSciences a regulatory foothold for the hardware, expanding options to monetize the device and its related IP, but without an AI algorithm the product cannot be sold immediately. The pending Fortitude transaction, if completed, would provide additional capital and a path to market for the combined entity, according to the company’s statement.
Key facts
- 1The FDA granted 510(k) clearance under submission number K260005. globenewswire.com
- 2The cleared device is a 12‑lead resting electrocardiograph for adult and pediatric patients in hospitals and other healthcare settings. globenewswire.com
- 3The clearance does not include the AI‑ECG algorithm. globenewswire.com
- 4HeartSciences said it has no commitment or timeline to commercialize the device without a cleared AI component. globenewswire.com
- 5The company expects the business combination with Fortitude Mining Holdings to close in Q4 2026, pending customary conditions and shareholder approval. globenewswire.com
- 6CEO Andrew Simpson said the clearance broadens potential routes to realize value from the device and its intellectual property. globenewswire.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.